Table 2.

Univariate Analysis of Adverse Effects in CRPC Patients Treated with Enzalutamide. Psoas Muscle Ratio, Body Fat, and Visceral Fat Volumes, and the V/S Ratio Were Used to Divide the Patients into Two Groups Following the Median Values for Each Parameter.

Parameter	Fatigue (>G2)			Anorexia (>G2)			Pain (>G2)			Insomnia (>G1)
	OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value
Age	1.012	0.939-1.091	0.744	1.075	0.984-1.176	0.108	0.942	0.858-1.033	0.208	1.018	0.901-1.151	0.765
Prior docetaxel
−	1			1			1			1
+	0.947	0.252-3.555	0.936	0.792	0.184-3.406	0.755	2.877	0.585-14.147	0.193	0.621	0.060-6.331	0.678
Corticosteroid
−	1			1			1			1
+	0.487	0.095-2.477	0.386	2.047	0.504-8.316	0.316	2.25	0.451-11.222	0.326	0.901	0.087-9.275	0.93
Psoas muscle ratio
<160.1	1			1			1			1
≥160.1	3.875	1.016-17.134	0.047	0.093	0.011-0.784	0.029	0.801	0.165-3.893	0.784	1.099	0.145-8.303	0.924
Body fat
<34.5	1			1			1			1
≥34.5	2.074	0.558-7.698	0.275	0.559	0.142-2.196	0.405	1.247	0.256-6.057	0.784	2.906	0.286-29.468	0.366
Visceral fat
<36.4	1			1			1			1
≥36.4	2.230	0.600-8.282	0.230	0.600	0.152-2.356	0.464	0.701	0.144-3.407	0.660	3.096	0.305-31.399	0.338
V/S ratio
<1.04	1			1			1			1
≥1.04	1.350	00381-4.776	0.641	4.444	0.866-22.783	0.073	0.327	0.058-1.821	0.202	2.906	0.286-29.468	0.366

G grade following the CTCAE criteria, version 4.1; CRPC castration-resistant prostate cancer; OR odds ratio; CI confidence interval

Psoas muscle ratio: psoas muscle volume/height, (cm³/m); body fat: (visceral fat + subcutaneous fat)/abdominal volume; V/S ratio: visceral fat/subcutaneous fat ratio